Nomad Power Solutions (NMAD) Total Current Liabilities (2010 - 2026)
Nomad Power Solutions (NMAD) posted Total Current Liabilities of $1.5 million for Q2 2026, up 12.52% on a QoQ basis from $1.3 million in Q4 2025, and up 179.27% year-over-year from $537122.0 in Q2 2025.
Analysis
Nomad Power Solutions (NMAD) Total Current Liabilities (2010 - 2026) Analysis & Trends
Nomad Power Solutions has reported Total Current Liabilities for 17 years, with the latest figure at $1.5 million in Q2 2026.
- On a quarterly basis, Total Current Liabilities rose 179.27% year-over-year to $1.5 million in Q2 2026; TTM through Jun 2026 was $1.5 million, a 179.27% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 318.84% from the prior year.
- Total Current Liabilities was $1.5 million for Q2 2026 at Nomad Power Solutions, up from $1.3 million in the prior quarter.
- The five-year high for Total Current Liabilities was $1.5 million in Q2 2026, with the low at $249987.0 in Q1 2023.
- Average Total Current Liabilities over 5 years is $531571.4, with a median of $408328.0 recorded in 2022.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities sank 61.22% in 2023, then jumped 318.84% in 2025.
- Over 5 years, Total Current Liabilities stood at $395756.0 in 2022, then declined by 20.69% to $313858.0 in 2023, then grew by 1.41% to $318284.0 in 2024, then surged by 318.84% to $1.3 million in 2025, then increased by 12.52% to $1.5 million in 2026.
- The last three Total Current Liabilities figures came in at $1.5 million (Q2 2026), $1.3 million (Q4 2025), and $521422.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Nomad Power Solutions | 49.59 Mn | 49.59 Mn | - | 1.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 521,422.00 |
| Jun 30, 2025 | 537,122.00 |
| Mar 31, 2025 | 355,098.00 |
| Dec 31, 2024 | 318,284.00 |
| Sep 30, 2024 | 328,956.00 |
| Jun 30, 2024 | 421,465.00 |
| Mar 31, 2024 | 462,836.00 |
| Dec 31, 2023 | 313,858.00 |
| Sep 30, 2023 | 311,736.00 |
| Jun 30, 2023 | 402,614.00 |
| Mar 31, 2023 | 249,987.00 |
| Dec 31, 2022 | 395,756.00 |
| Sep 30, 2022 | 408,328.00 |
| Jun 30, 2022 | 531,540.00 |
| Mar 31, 2022 | 644,593.00 |
| Dec 31, 2021 | 302,926.00 |
| Sep 30, 2021 | 258,699.00 |
| Jun 30, 2021 | 376,326.00 |